BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 32164585)

  • 21. A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family.
    Yang X; Shang L; Yang L; Sun L; Tuo X; Ma S; Zhao L; Li X; Yang W
    Oncologist; 2024 Jun; 29(6):e837-e842. PubMed ID: 38159086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.
    Kramer C; Lanjouw L; Ruano D; Ter Elst A; Santandrea G; Solleveld-Westerink N; Werner N; van der Hout AH; de Kroon CD; van Wezel T; Berger L; Jalving M; Wesseling J; Smit V; de Bock GH; van Asperen CJ; Mourits M; Vreeswijk M; Bart J; Bosse T
    J Pathol; 2024 Feb; 262(2):137-146. PubMed ID: 37850614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer.
    Li L; Chen F; Lin A; Wang D; Shi Y; Chen G
    Comput Math Methods Med; 2021; 2021():4854282. PubMed ID: 34721658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A
    BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study.
    Huang Y; Qiu Y; Ding L; Ren S; Jiang Y; Luo J; Huang J; Yin X; Fu S; Zhao J; Hu K; Liao J
    J Pathol Clin Res; 2024 Mar; 10(2):e12367. PubMed ID: 38504382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature.
    Gaubert A; Kervarrec T; Montaudié H; Burel-Vandenbos F; Cardot-Leccia N; Di Mauro I; Fabas T; Tallet A; Kubiniek V; Pedeutour F; Dadone-Montaudié B
    J Invest Dermatol; 2023 Jul; 143(7):1178-1186. PubMed ID: 36754117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
    Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
    Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correspondence on 'Survival outcomes in patients with
    Verit FF; Demirkiran F
    Int J Gynecol Cancer; 2023 Dec; 33(12):1988. PubMed ID: 37730730
    [No Abstract]   [Full Text] [Related]  

  • 30. Case report: olaparib use in metastatic lung adenocarcinoma with
    Soon Jian Hao J; Hoai CS; Weng DTS; Ngeow J; Chiang J
    Cold Spring Harb Mol Case Stud; 2022 Dec; 8(7):. PubMed ID: 36577523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    Balendran S; Liebmann-Reindl S; Berghoff AS; Reischer T; Popitsch N; Geier CB; Kenner L; Birner P; Streubel B; Preusser M
    J Neurooncol; 2017 Jul; 133(3):469-476. PubMed ID: 28497333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biological effects and clinical implications of BRCA mutations: where do we go from here?
    Stoppa-Lyonnet D
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
    Pham MM; Avila M; Hinchcliff E; Westin SN
    Cancer Treat Res; 2023; 186():71-89. PubMed ID: 37978131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deleterious and ethnic-related BRCA1/2 mutations in tissue and blood of Egyptian colorectal cancer patients and its correlation with human papillomavirus.
    Youssef ASE; Zekri ARN; Mohanad M; Loutfy SA; Abdel Fattah NF; Elberry MH; El Leithy AA; El-Touny A; Rabie AS; Shalaby M; Hanafy A; Lotfy MM; El-Sisi ER; El-Sayyad GS; Nassar A
    Clin Exp Med; 2023 Dec; 23(8):5063-5088. PubMed ID: 37804357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    De Mattos-Arruda L; Bidard FC; Won HH; Cortes J; Ng CK; Peg V; Nuciforo P; Jungbluth AA; Weigelt B; Berger MF; Seoane J; Reis-Filho JS
    Mol Oncol; 2014 Feb; 8(1):150-8. PubMed ID: 24220311
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Chao A; Lin YH; Yang LY; Wu RC; Chang WY; Chang PY; Chang SC; Lin CY; Huang HJ; Lin CT; Chou HH; Huang KG; Kuo WL; Chang TC; Lai CH
    J Gynecol Oncol; 2020 May; 31(3):e24. PubMed ID: 31912679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
    Khalique S; Pettitt SJ; Kelly G; Tunariu N; Natrajan R; Banerjee S; Lord CJ
    J Pathol Clin Res; 2020 Jan; 6(1):3-11. PubMed ID: 31577852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Morse CB; Norquist BM; Harrell MI; Agnew KJ; Gray HJ; Urban RR; Garcia RL; Goff BA; Swisher EM
    Gynecol Oncol; 2016 Nov; 143(2):389-392. PubMed ID: 27575909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer.
    Kim YN; Shim Y; Seo J; Choi Z; Lee YJ; Shin S; Kim SW; Kim S; Choi JR; Lee JY; Lee ST
    Clin Cancer Res; 2023 Jul; 29(14):2725-2734. PubMed ID: 37067525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.